GSK names Luke Miels as next CEO
Miels will formally assume the role on January 1, 2026
Miels will formally assume the role on January 1, 2026
Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price
The Hub & Spoke model is designed to extend advanced medical care to a wider community
LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment
Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines
The collaboration is expected to facilitate access to world-class treatments and specialised care for Iraqi personnel
New infrastructure makes it possible for healthcare organizations to integrate AI agents seamlessly into critical workflows like benefit verification and prior authorization
Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Subscribe To Our Newsletter & Stay Updated